2015 Form 10-K Financial Statement

#000078516116000117 Filed on February 25, 2016

View on sec.gov

Income Statement

Concept 2015 2014 Q4 2014 Q3
Revenue $3.163B $613.4M $596.9M
YoY Change 31.46% 7.22% 5.83%
Cost Of Revenue $128.7M $29.90M $26.60M
YoY Change 15.01% 10.33% 4.31%
Gross Profit $2.987B $576.9M $562.1M
YoY Change 32.03% 6.56% 5.96%
Gross Profit Margin 94.44% 94.05% 94.17%
Selling, General & Admin $1.868B $348.9M $331.8M
YoY Change 39.15% 10.59% 5.6%
% of Gross Profit 62.55% 60.48% 59.03%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $139.7M $27.50M $27.40M
YoY Change 29.71% 9.13% 12.76%
% of Gross Profit 4.68% 4.77% 4.87%
Operating Expenses $2.433B $467.8M $448.6M
YoY Change 35.4% 10.75% 6.63%
Operating Profit $485.7M $109.1M $113.5M
YoY Change 4.29% -8.32% 3.37%
Interest Expense $142.9M -$23.80M -$25.90M
YoY Change 30.86% 1.28% 11.16%
% of Operating Profit 29.42% -21.81% -22.82%
Other Income/Expense, Net $0.00 $1.100M $200.0K
YoY Change -15.38% -66.67%
Pretax Income $395.6M $74.10M $87.80M
YoY Change 2.25% -21.67% -19.0%
Income Tax $141.9M $19.30M $22.10M
% Of Pretax Income 35.87% 26.05% 25.17%
Net Earnings $183.1M $42.10M $50.10M
YoY Change -17.52% -13.91% -13.92%
Net Earnings / Revenue 5.79% 6.86% 8.39%
Basic Earnings Per Share $2.02 $0.46 $0.55
Diluted Earnings Per Share $1.91 $0.44 $0.52
COMMON SHARES
Basic Shares Outstanding 89.40M shares 87.75M shares 86.50M shares
Diluted Shares Outstanding 101.0M shares 100.5M shares

Balance Sheet

Concept 2015 2014 Q4 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $61.60M $66.70M $272.3M
YoY Change -7.65% 3.41% 318.92%
Cash & Equivalents $61.60M $66.70M $272.3M
Short-Term Investments
Other Short-Term Assets $126.6M $108.3M $110.2M
YoY Change -57.33% -5.91% -7.55%
Inventory
Prepaid Expenses
Receivables $403.3M $323.2M $261.6M
Other Receivables $7.200M $13.90M $0.00
Total Short-Term Assets $598.7M $686.6M $783.0M
YoY Change -12.8% 18.3% 36.15%
LONG-TERM ASSETS
Property, Plant & Equipment $1.310B $1.020B $994.6M
YoY Change 28.48% 11.99% 11.32%
Goodwill $1.084B $491.7M
YoY Change 137.25% 7.55%
Intangibles $306.1M $99.90M
YoY Change 247.05% 14.43%
Long-Term Investments $8.200M
YoY Change -56.61%
Other Assets $387.8M $162.5M $169.5M
YoY Change 32.85% 12.77% 29.59%
Total Long-Term Assets $4.007B $2.702B $2.011B
YoY Change 48.33% 38.27% 1.49%
TOTAL ASSETS
Total Short-Term Assets $598.7M $686.6M $783.0M
Total Long-Term Assets $4.007B $2.702B $2.011B
Total Assets $4.606B $3.388B $2.794B
YoY Change 35.94% 33.69% 9.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $61.60M $53.40M $54.80M
YoY Change 15.36% -13.73% 1.11%
Accrued Expenses $155.9M $144.5M $251.4M
YoY Change 7.89% 26.09% -2.41%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $36.80M $20.80M $208.5M
YoY Change 76.92% 69.11%
Total Short-Term Liabilities $426.4M $364.3M $514.7M
YoY Change 17.05% 16.91% 65.07%
LONG-TERM LIABILITIES
Long-Term Debt $3.135B $2.090B $1.441B
YoY Change 49.96% 38.88% 10.35%
Other Long-Term Liabilities $144.6M $37.50M $139.7M
YoY Change 6.17% -14.77% -0.5%
Total Long-Term Liabilities $3.279B $37.50M $139.7M
YoY Change 47.28% -14.77% -0.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $426.4M $364.3M $514.7M
Total Long-Term Liabilities $3.279B $37.50M $139.7M
Total Liabilities $3.995B $2.591B $2.096B
YoY Change 41.56% 32.26% 19.19%
SHAREHOLDERS EQUITY
Retained Earnings -$1.879B -$1.921B
YoY Change -10.57% -10.64%
Common Stock $1.000M $1.000M
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $458.7M $458.1M
YoY Change 13.37% 13.33%
Treasury Stock Shares 16.27M shares 16.26M shares
Shareholders Equity $611.4M $473.2M $449.6M
YoY Change
Total Liabilities & Shareholders Equity $4.606B $3.388B $2.794B
YoY Change 35.94% 33.69% 9.29%

Cashflow Statement

Concept 2015 2014 Q4 2014 Q3
OPERATING ACTIVITIES
Net Income $183.1M $42.10M $50.10M
YoY Change -17.52% -13.91% -13.92%
Depreciation, Depletion And Amortization $139.7M $27.50M $27.40M
YoY Change 29.71% 9.13% 12.76%
Cash From Operating Activities $502.0M $70.20M $139.6M
YoY Change 10.43% -30.43% -2.1%
INVESTING ACTIVITIES
Capital Expenditures $128.4M -$41.40M -$46.00M
YoY Change -24.87% 21.41% -54.68%
Acquisitions $985.1M $0.00
YoY Change 41.78%
Other Investing Activities $1.100M -$673.2M -$9.300M
YoY Change -147.83% -13300.0% -263.16%
Cash From Investing Activities -$1.130B -$714.6M -$55.30M
YoY Change 28.84% 2364.14% -42.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $45.30M
YoY Change 5.1%
Debt Paid & Issued, Net $597.4M
YoY Change 97.42%
Cash From Financing Activities $622.7M 438.8M 122.2M
YoY Change 46.69% -706.08% -341.98%
NET CHANGE
Cash From Operating Activities $502.0M 70.20M 139.6M
Cash From Investing Activities -$1.130B -714.6M -55.30M
Cash From Financing Activities $622.7M 438.8M 122.2M
Net Change In Cash -$5.100M -205.6M 206.5M
YoY Change -331.82% 41020.0% -5681.08%
FREE CASH FLOW
Cash From Operating Activities $502.0M $70.20M $139.6M
Capital Expenditures $128.4M -$41.40M -$46.00M
Free Cash Flow $373.6M $111.6M $185.6M
YoY Change 31.69% -17.33% -23.97%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2009Q3 hls Common Stock Shares Issued Consolidated Securities Action Settlement
CommonStockSharesIssuedConsolidatedSecuritiesActionSettlement
5000000 shares
CY2009Q3 hls Common Stock Warrants Issued Consolidated Securities Action Settlement
CommonStockWarrantsIssuedConsolidatedSecuritiesActionSettlement
8200000 shares
CY2014Q1 hls Classof Warrantor Right Exercise Rateof Warrantsor Rights
ClassofWarrantorRightExerciseRateofWarrantsorRights
0.2021 shares
CY2015 dei Amendment Flag
AmendmentFlag
false
CY2015 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2015 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015 dei Document Period End Date
DocumentPeriodEndDate
2015-12-31
CY2015 dei Document Type
DocumentType
10-K
CY2015 dei Entity Central Index Key
EntityCentralIndexKey
0000785161
CY2016Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
89777044 shares
CY2015 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2015 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2015Q2 dei Entity Public Float
EntityPublicFloat
4000000000 USD
CY2015 dei Entity Registrant Name
EntityRegistrantName
HEALTHSOUTH CORP
CY2015 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2015 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2014Q4 hls Accountsand Other Receivable Net
AccountsandOtherReceivableNet
374600000 USD
CY2015Q4 hls Accountsand Other Receivable Net
AccountsandOtherReceivableNet
507100000 USD
CY2013 hls Adjustmentsto Additional Paidin Capital Tax Impact Of Equity Componentof Convertible Debt
AdjustmentstoAdditionalPaidinCapitalTaxImpactOfEquityComponentofConvertibleDebt
-28000000 USD
CY2013Q4 hls Affiliates Ownership Percentage
AffiliatesOwnershipPercentage
1.00
CY2014Q4 hls Allowance For Doubtful Accounts As Percentage Of Patient Accounts Receivable
AllowanceForDoubtfulAccountsAsPercentageOfPatientAccountsReceivable
0.107
CY2015Q4 hls Allowance For Doubtful Accounts As Percentage Of Patient Accounts Receivable
AllowanceForDoubtfulAccountsAsPercentageOfPatientAccountsReceivable
0.125
CY2012Q4 hls Allowancefor Doubtful Accounts Receivable Currentand Noncurrent
AllowanceforDoubtfulAccountsReceivableCurrentandNoncurrent
28700000 USD
CY2013Q4 hls Allowancefor Doubtful Accounts Receivable Currentand Noncurrent
AllowanceforDoubtfulAccountsReceivableCurrentandNoncurrent
33100000 USD
CY2014Q4 hls Allowancefor Doubtful Accounts Receivable Currentand Noncurrent
AllowanceforDoubtfulAccountsReceivableCurrentandNoncurrent
43000000 USD
CY2015Q4 hls Allowancefor Doubtful Accounts Receivable Currentand Noncurrent
AllowanceforDoubtfulAccountsReceivableCurrentandNoncurrent
71600000 USD
CY2015Q2 hls Capitalexpenditurespermitted
Capitalexpenditurespermitted
200000000 USD
CY2015Q2 hls Capitalexpenditurespermitted
Capitalexpenditurespermitted
350000000 USD
CY2012Q4 hls Classof Warrant Exercise Priceof Warrants
ClassofWarrantExercisePriceofWarrants
32.50
CY2014Q4 hls Classof Warrant Exercise Priceof Warrants
ClassofWarrantExercisePriceofWarrants
32.50
CY2009Q3 hls Classof Warrant Exercise Priceof Warrants
ClassofWarrantExercisePriceofWarrants
41.40
CY2014Q1 hls Classof Warrant Exercise Priceof Warrants
ClassofWarrantExercisePriceofWarrants
32.16
CY2015Q4 hls Compliance Threshold Under Health Care Act
ComplianceThresholdUnderHealthCareAct
0.60
CY2015Q4 hls Consolidatedcoverageratiominimum
Consolidatedcoverageratiominimum
2
CY2006Q1 hls Convertible Preferred Stock Conversion Price
ConvertiblePreferredStockConversionPrice
30.50
CY2013 hls Convertibledebtissued
Convertibledebtissued
320000000 USD
CY2014 hls Convertibledebtissued
Convertibledebtissued
0 USD
CY2015 hls Convertibledebtissued
Convertibledebtissued
0 USD
CY2014Q4 hls Deferred Tax Asset Property Plant And Equipment
DeferredTaxAssetPropertyPlantAndEquipment
40700000 USD
CY2015Q4 hls Deferred Tax Asset Property Plant And Equipment
DeferredTaxAssetPropertyPlantAndEquipment
48200000 USD
CY2014Q4 hls Deferredtaxassets Noncontrollinginterest
DeferredtaxassetsNoncontrollinginterest
0 USD
CY2015Q4 hls Deferredtaxassets Noncontrollinginterest
DeferredtaxassetsNoncontrollinginterest
10600000 USD
CY2014Q4 hls Deferredtaxliabilitiesconvertibledebtinterest
Deferredtaxliabilitiesconvertibledebtinterest
31700000 USD
CY2015Q4 hls Deferredtaxliabilitiesconvertibledebtinterest
Deferredtaxliabilitiesconvertibledebtinterest
35300000 USD
CY2013Q4 hls Divested Skilled Nursing Facility Beds
DivestedSkilledNursingFacilityBeds
41
CY2013 hls Equity In Net Income Of Consolidated Affiliates
EquityInNetIncomeOfConsolidatedAffiliates
0 USD
CY2014 hls Equity In Net Income Of Consolidated Affiliates
EquityInNetIncomeOfConsolidatedAffiliates
0 USD
CY2015 hls Equity In Net Income Of Consolidated Affiliates
EquityInNetIncomeOfConsolidatedAffiliates
0 USD
CY2013 hls Equity Method Investment Summarized Financial Information Operating Expenses
EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses
-43600000 USD
CY2014 hls Equity Method Investment Summarized Financial Information Operating Expenses
EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses
-25900000 USD
CY2015 hls Equity Method Investment Summarized Financial Information Operating Expenses
EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses
-15000000 USD
CY2014Q4 hls Equity Method Investments Cumulative Share Of Distributions
EquityMethodInvestmentsCumulativeShareOfDistributions
-69900000 USD
CY2015Q4 hls Equity Method Investments Cumulative Share Of Distributions
EquityMethodInvestmentsCumulativeShareOfDistributions
-77500000 USD
CY2014Q4 hls Equity Method Investments Cumulative Share Of Income
EquityMethodInvestmentsCumulativeShareOfIncome
77300000 USD
CY2015Q4 hls Equity Method Investments Cumulative Share Of Income
EquityMethodInvestmentsCumulativeShareOfIncome
88000000 USD
CY2013 hls Equityrolloverfromabusinesscombination
Equityrolloverfromabusinesscombination
0 USD
CY2014 hls Equityrolloverfromabusinesscombination
Equityrolloverfromabusinesscombination
64500000 USD
CY2015 hls Equityrolloverfromabusinesscombination
Equityrolloverfromabusinesscombination
0 USD
CY2014Q1 hls Expirationof Warrants
ExpirationofWarrants
100000 shares
CY2015Q4 hls Financial Covenants Leverage Ratio Maximum
FinancialCovenantsLeverageRatioMaximum
4.50
CY2015Q3 hls Financial Covenants Leverage Ratio Maximum
FinancialCovenantsLeverageRatioMaximum
4.25
CY2015Q3 hls Financial Covenants Leverage Ratio Maximum
FinancialCovenantsLeverageRatioMaximum
4.50
CY2014Q4 hls Fully Depreciated Assets
FullyDepreciatedAssets
240900000 USD
CY2015Q4 hls Fully Depreciated Assets
FullyDepreciatedAssets
252400000 USD
CY2013 hls Government Class Action And Related Settlements Gain Loss
GovernmentClassActionAndRelatedSettlementsGainLoss
-23500000 USD
CY2014 hls Government Class Action And Related Settlements Gain Loss
GovernmentClassActionAndRelatedSettlementsGainLoss
-1700000 USD
CY2015 hls Government Class Action And Related Settlements Gain Loss
GovernmentClassActionAndRelatedSettlementsGainLoss
7500000 USD
CY2013 hls Gross Realized Gains Losses Availableforsale Securities Sale Proceedsand Increase Decreaseon Derivative
GrossRealizedGainsLossesAvailableforsaleSecuritiesSaleProceedsandIncreaseDecreaseonDerivative
0 USD
CY2014 hls Gross Realized Gains Losses Availableforsale Securities Sale Proceedsand Increase Decreaseon Derivative
GrossRealizedGainsLossesAvailableforsaleSecuritiesSaleProceedsandIncreaseDecreaseonDerivative
0 USD
CY2015 hls Gross Realized Gains Losses Availableforsale Securities Sale Proceedsand Increase Decreaseon Derivative
GrossRealizedGainsLossesAvailableforsaleSecuritiesSaleProceedsandIncreaseDecreaseonDerivative
3200000 USD
CY2013 hls Healthcare Plan Expense
HealthcarePlanExpense
73400000 USD
CY2014 hls Healthcare Plan Expense
HealthcarePlanExpense
85200000 USD
CY2015 hls Healthcare Plan Expense
HealthcarePlanExpense
109300000 USD
CY2013 hls Income Loss From Continuing Operations Attributable To Common Shareholders Diluted
IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted
325700000 USD
CY2014 hls Income Loss From Continuing Operations Attributable To Common Shareholders Diluted
IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted
225500000 USD
CY2015 hls Income Loss From Continuing Operations Attributable To Common Shareholders Diluted
IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted
193400000 USD
CY2013 hls Income Lossfrom Continuing Operations Attributableto Common Shareholders Basicand Diluted
IncomeLossfromContinuingOperationsAttributabletoCommonShareholdersBasicandDiluted
228700000 USD
CY2014 hls Income Lossfrom Continuing Operations Attributableto Common Shareholders Basicand Diluted
IncomeLossfromContinuingOperationsAttributabletoCommonShareholdersBasicandDiluted
207900000 USD
CY2015 hls Income Lossfrom Continuing Operations Attributableto Common Shareholders Basicand Diluted
IncomeLossfromContinuingOperationsAttributabletoCommonShareholdersBasicandDiluted
181400000 USD
CY2013Q2 hls Increase Decrease Net Operating Loss Carryforward Gross
IncreaseDecreaseNetOperatingLossCarryforwardGross
283000000 USD
CY2015 hls Initial Suspension Periodof Medicare Payments
InitialSuspensionPeriodofMedicarePayments
P180D
CY2014Q4 hls Investments Total
InvestmentsTotal
162800000 USD
CY2015Q4 hls Investments Total
InvestmentsTotal
163700000 USD
CY2015Q4 hls Maximum Self Insured Risk
MaximumSelfInsuredRisk
25000000 USD
CY2015Q4 hls Medicare Denials Percentage Collected After Appeal
MedicareDenialsPercentageCollectedAfterAppeal
0.71
CY2015Q4 hls Medicare Denials Percentage Collected After Appeal Including Administrative Law Judge Hearings
MedicareDenialsPercentageCollectedAfterAppealIncludingAdministrativeLawJudgeHearings
0.70
CY2015Q4 hls Minimum Amount Of Loss Contingency To Consider When Accruing Estimate Of Related Legal Fees
MinimumAmountOfLossContingencyToConsiderWhenAccruingEstimateOfRelatedLegalFees
5000000 USD
CY2013 hls Net Income Loss Availableto Common Stockholders
NetIncomeLossAvailabletoCommonStockholders
227600000 USD
CY2014 hls Net Income Loss Availableto Common Stockholders
NetIncomeLossAvailabletoCommonStockholders
213300000 USD
CY2015 hls Net Income Loss Availableto Common Stockholders
NetIncomeLossAvailabletoCommonStockholders
180500000 USD
CY2013 hls Net Operating Revenues Less Provision For Doubtful Accounts
NetOperatingRevenuesLessProvisionForDoubtfulAccounts
2247200000 USD
CY2014 hls Net Operating Revenues Less Provision For Doubtful Accounts
NetOperatingRevenuesLessProvisionForDoubtfulAccounts
2374300000 USD
CY2015 hls Net Operating Revenues Less Provision For Doubtful Accounts
NetOperatingRevenuesLessProvisionForDoubtfulAccounts
3115700000 USD
CY2015Q4 hls Number Of General Or Limited Partnerships Limited Liability Companies Or Joint Ventures
NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures
6 facilities
CY2014Q4 hls Number Of Individual Claims Covered By Self Insured Risk Reserves
NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves
1100
CY2015Q4 hls Number Of Individual Claims Covered By Self Insured Risk Reserves
NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves
1100
CY2015Q4 hls Number Of Partially Owned Subsidiaries Nonconsolidated
NumberOfPartiallyOwnedSubsidiariesNonconsolidated
7 facilities
CY2015Q4 hls Number Of Sale Leaseback Transactions
NumberOfSaleLeasebackTransactions
2
CY2014Q4 hls Numberof Home Health Locations Before Encompass Acquisition
NumberofHomeHealthLocationsBeforeEncompassAcquisition
25
CY2013 hls Occupancy Cost
OccupancyCost
47000000 USD
CY2014 hls Occupancy Cost
OccupancyCost
41600000 USD
CY2015 hls Occupancy Cost
OccupancyCost
53900000 USD
CY2015Q4 hls Operating And Capital Leases Future Minimum Payments Due
OperatingAndCapitalLeasesFutureMinimumPaymentsDue
930700000 USD
CY2015Q4 hls Operating And Capital Leases Future Minimum Payments Due Current
OperatingAndCapitalLeasesFutureMinimumPaymentsDueCurrent
92000000 USD
CY2015Q4 hls Operating And Capital Leases Future Minimum Payments Due In Five Years
OperatingAndCapitalLeasesFutureMinimumPaymentsDueInFiveYears
60700000 USD
CY2015Q4 hls Operating And Capital Leases Future Minimum Payments Due In Four Years
OperatingAndCapitalLeasesFutureMinimumPaymentsDueInFourYears
71500000 USD
CY2015Q4 hls Operating And Capital Leases Future Minimum Payments Due In Three Years
OperatingAndCapitalLeasesFutureMinimumPaymentsDueInThreeYears
79400000 USD
CY2015Q4 hls Operating And Capital Leases Future Minimum Payments Due In Two Years
OperatingAndCapitalLeasesFutureMinimumPaymentsDueInTwoYears
86200000 USD
CY2015Q4 hls Operating And Capital Leases Future Minimum Payments Due Thereafter
OperatingAndCapitalLeasesFutureMinimumPaymentsDueThereafter
540900000 USD
CY2014Q1 hls Operating Earnings
OperatingEarnings
105800000 USD
CY2014Q2 hls Operating Earnings
OperatingEarnings
115400000 USD
CY2014Q3 hls Operating Earnings
OperatingEarnings
100700000 USD
CY2014Q4 hls Operating Earnings
OperatingEarnings
96500000 USD
CY2014 hls Operating Earnings
OperatingEarnings
418400000 USD
CY2015Q1 hls Operating Earnings
OperatingEarnings
105600000 USD
CY2015Q2 hls Operating Earnings
OperatingEarnings
123400000 USD
CY2015Q3 hls Operating Earnings
OperatingEarnings
121200000 USD
CY2015Q4 hls Operating Earnings
OperatingEarnings
135500000 USD
CY2015 hls Operating Earnings
OperatingEarnings
485700000 USD
CY2015Q4 hls Operating Lease Term Maximum
OperatingLeaseTermMaximum
15 Y
CY2015Q4 hls Operating Lease Term Minimum
OperatingLeaseTermMinimum
3 Y
CY2013 hls Operating Leases Rent Expense Other
OperatingLeasesRentExpenseOther
4200000 USD
CY2014 hls Operating Leases Rent Expense Other
OperatingLeasesRentExpenseOther
3900000 USD
CY2015 hls Operating Leases Rent Expense Other
OperatingLeasesRentExpenseOther
3800000 USD
CY2007Q4 hls Option Contract Annual Premium
OptionContractAnnualPremium
0.15
CY2007Q4 hls Option Contract Exercisable
OptionContractExercisable
0.30
CY2015Q2 hls Option Contract Exercisable
OptionContractExercisable
0.30
CY2014Q4 hls Other Notes Payable Other
OtherNotesPayableOther
300000 USD
CY2015Q4 hls Other Notes Payable Other
OtherNotesPayableOther
300000 USD
CY2015 hls Ownership Percentage Of Subsidiary Guarantors
OwnershipPercentageOfSubsidiaryGuarantors
1.00
CY2014Q4 hls Patient Accounts Receivable Net Current
PatientAccountsReceivableNetCurrent
309300000 USD
CY2015Q4 hls Patient Accounts Receivable Net Current
PatientAccountsReceivableNetCurrent
403300000 USD
CY2014Q4 hls Patient Accounts Receivable Net Noncurrent
PatientAccountsReceivableNetNoncurrent
51400000 USD
CY2015Q4 hls Patient Accounts Receivable Net Noncurrent
PatientAccountsReceivableNetNoncurrent
96600000 USD
CY2013 hls Percentage Of Net Operating Revenues Managed Care
PercentageOfNetOperatingRevenuesManagedCare
0.185
CY2014 hls Percentage Of Net Operating Revenues Managed Care
PercentageOfNetOperatingRevenuesManagedCare
0.186
CY2015 hls Percentage Of Net Operating Revenues Managed Care
PercentageOfNetOperatingRevenuesManagedCare
0.177
CY2013 hls Percentage Of Net Operating Revenues Medicaid
PercentageOfNetOperatingRevenuesMedicaid
0.012
CY2014 hls Percentage Of Net Operating Revenues Medicaid
PercentageOfNetOperatingRevenuesMedicaid
0.018
CY2015 hls Percentage Of Net Operating Revenues Medicaid
PercentageOfNetOperatingRevenuesMedicaid
0.030
CY2013 hls Percentage Of Net Operating Revenues Medicare
PercentageOfNetOperatingRevenuesMedicare
0.745
CY2014 hls Percentage Of Net Operating Revenues Medicare
PercentageOfNetOperatingRevenuesMedicare
0.741
CY2015 hls Percentage Of Net Operating Revenues Medicare
PercentageOfNetOperatingRevenuesMedicare
0.749
CY2013 hls Percentage Of Net Operating Revenues Other Income
PercentageOfNetOperatingRevenuesOtherIncome
0.017
CY2014 hls Percentage Of Net Operating Revenues Other Income
PercentageOfNetOperatingRevenuesOtherIncome
0.015
CY2015 hls Percentage Of Net Operating Revenues Other Income
PercentageOfNetOperatingRevenuesOtherIncome
0.012
CY2013 hls Percentage Of Net Operating Revenues Other Third Party Payors
PercentageOfNetOperatingRevenuesOtherThirdPartyPayors
0.018
CY2014 hls Percentage Of Net Operating Revenues Other Third Party Payors
PercentageOfNetOperatingRevenuesOtherThirdPartyPayors
0.018
CY2015 hls Percentage Of Net Operating Revenues Other Third Party Payors
PercentageOfNetOperatingRevenuesOtherThirdPartyPayors
0.017
CY2013 hls Percentage Of Net Operating Revenues Patients
PercentageOfNetOperatingRevenuesPatients
0.011
CY2014 hls Percentage Of Net Operating Revenues Patients
PercentageOfNetOperatingRevenuesPatients
0.010
CY2015 hls Percentage Of Net Operating Revenues Patients
PercentageOfNetOperatingRevenuesPatients
0.006
CY2013 hls Percentage Of Net Operating Revenues Total
PercentageOfNetOperatingRevenuesTotal
1.000
CY2014 hls Percentage Of Net Operating Revenues Total
PercentageOfNetOperatingRevenuesTotal
1.000
CY2015 hls Percentage Of Net Operating Revenues Total
PercentageOfNetOperatingRevenuesTotal
1.000
CY2013 hls Percentage Of Net Operating Revenues Workers Compensation
PercentageOfNetOperatingRevenuesWorkersCompensation
0.012
CY2014 hls Percentage Of Net Operating Revenues Workers Compensation
PercentageOfNetOperatingRevenuesWorkersCompensation
0.012
CY2015 hls Percentage Of Net Operating Revenues Workers Compensation
PercentageOfNetOperatingRevenuesWorkersCompensation
0.009
CY2014Q4 hls Percentage Of Net Patient Service Accounts Receivable
PercentageOfNetPatientServiceAccountsReceivable
1.000
CY2015Q4 hls Percentage Of Net Patient Service Accounts Receivable
PercentageOfNetPatientServiceAccountsReceivable
1.000
CY2014Q4 hls Percentage Of Net Patient Service Accounts Receivable Managed Care And Other Discount Plans
PercentageOfNetPatientServiceAccountsReceivableManagedCareAndOtherDiscountPlans
0.185
CY2015Q4 hls Percentage Of Net Patient Service Accounts Receivable Managed Care And Other Discount Plans
PercentageOfNetPatientServiceAccountsReceivableManagedCareAndOtherDiscountPlans
0.197
CY2014Q4 hls Percentage Of Net Patient Service Accounts Receivable Medicaid
PercentageOfNetPatientServiceAccountsReceivableMedicaid
0.018
CY2015Q4 hls Percentage Of Net Patient Service Accounts Receivable Medicaid
PercentageOfNetPatientServiceAccountsReceivableMedicaid
0.029
CY2014Q4 hls Percentage Of Net Patient Service Accounts Receivable Medicare
PercentageOfNetPatientServiceAccountsReceivableMedicare
0.722
CY2015Q4 hls Percentage Of Net Patient Service Accounts Receivable Medicare
PercentageOfNetPatientServiceAccountsReceivableMedicare
0.705
CY2014Q4 hls Percentage Of Net Patient Service Accounts Receivable Other Third Party Payors
PercentageOfNetPatientServiceAccountsReceivableOtherThirdPartyPayors
0.038
CY2015Q4 hls Percentage Of Net Patient Service Accounts Receivable Other Third Party Payors
PercentageOfNetPatientServiceAccountsReceivableOtherThirdPartyPayors
0.041
CY2014Q4 hls Percentage Of Net Patient Service Accounts Receivable Patients
PercentageOfNetPatientServiceAccountsReceivablePatients
0.018
CY2015Q4 hls Percentage Of Net Patient Service Accounts Receivable Patients
PercentageOfNetPatientServiceAccountsReceivablePatients
0.009
CY2014Q4 hls Percentage Of Net Patient Service Accounts Receivable Workers Compensation
PercentageOfNetPatientServiceAccountsReceivableWorkersCompensation
0.019
CY2015Q4 hls Percentage Of Net Patient Service Accounts Receivable Workers Compensation
PercentageOfNetPatientServiceAccountsReceivableWorkersCompensation
0.019
CY2008Q1 hls Percentage Of Net Profit Due Company From Hospital Building Sale
PercentageOfNetProfitDueCompanyFromHospitalBuildingSale
0.40
CY2015Q4 hls Percentageofassetspledgedtolendersundercreditagreement
Percentageofassetspledgedtolendersundercreditagreement
0.75
CY2013 hls Premium Paid On Redemption Of Bonds
PremiumPaidOnRedemptionOfBonds
1700000 USD
CY2014 hls Premium Paid On Redemption Of Bonds
PremiumPaidOnRedemptionOfBonds
10600000 USD
CY2015 hls Premium Paid On Redemption Of Bonds
PremiumPaidOnRedemptionOfBonds
13700000 USD
CY2013 hls Premiumreceivedonbondissuance
Premiumreceivedonbondissuance
0 USD
CY2014 hls Premiumreceivedonbondissuance
Premiumreceivedonbondissuance
6300000 USD
CY2015 hls Premiumreceivedonbondissuance
Premiumreceivedonbondissuance
9800000 USD
CY2013 hls Professional Fees Accounting Tax And Legal
ProfessionalFeesAccountingTaxAndLegal
9500000 USD
CY2014 hls Professional Fees Accounting Tax And Legal
ProfessionalFeesAccountingTaxAndLegal
9300000 USD
CY2015 hls Professional Fees Accounting Tax And Legal
ProfessionalFeesAccountingTaxAndLegal
3000000 USD
CY2014Q4 hls Property And Equipment Net Excluding Cip
PropertyAndEquipmentNetExcludingCIP
991100000 USD
CY2015Q4 hls Property And Equipment Net Excluding Cip
PropertyAndEquipmentNetExcludingCIP
1259000000 USD
CY2014 hls Reductionin Net Operating Revenue Post Payment Claims
ReductioninNetOperatingRevenuePostPaymentClaims
400000 USD
CY2015 hls Reductionin Net Operating Revenue Post Payment Claims
ReductioninNetOperatingRevenuePostPaymentClaims
-600000 USD
CY2013 hls Repurchaseofpreferredstock
Repurchaseofpreferredstock
320000000 USD
CY2014 hls Repurchaseofpreferredstock
Repurchaseofpreferredstock
0 USD
CY2015 hls Repurchaseofpreferredstock
Repurchaseofpreferredstock
0 USD
CY2015Q4 hls Retirement Investment Plan Age Requirement
RetirementInvestmentPlanAgeRequirement
21
CY2015 hls Retirement Investment Plan Company Match
RetirementInvestmentPlanCompanyMatch
50% of the first 6% of each participant’s elective deferrals
CY2013 hls Retirement Investment Plan Company Match Funded By Plan Forfeiture Account
RetirementInvestmentPlanCompanyMatchFundedByPlanForfeitureAccount
500000 USD
CY2014 hls Retirement Investment Plan Company Match Funded By Plan Forfeiture Account
RetirementInvestmentPlanCompanyMatchFundedByPlanForfeitureAccount
500000 USD
CY2015 hls Retirement Investment Plan Company Match Funded By Plan Forfeiture Account
RetirementInvestmentPlanCompanyMatchFundedByPlanForfeitureAccount
900000 USD
CY2013 hls Retirement Investment Plan Company Match Total Costs
RetirementInvestmentPlanCompanyMatchTotalCosts
13200000 USD
CY2014 hls Retirement Investment Plan Company Match Total Costs
RetirementInvestmentPlanCompanyMatchTotalCosts
13900000 USD
CY2015 hls Retirement Investment Plan Company Match Total Costs
RetirementInvestmentPlanCompanyMatchTotalCosts
15000000 USD
CY2015Q4 hls Retirement Investment Plan Company Match Vesting Percentage
RetirementInvestmentPlanCompanyMatchVestingPercentage
1.00
CY2015Q4 hls Retirement Investment Plan Company Match Vesting Period
RetirementInvestmentPlanCompanyMatchVestingPeriod
3 Y
CY2015Q4 hls Retirement Investment Plan Maximum Employee Contribution
RetirementInvestmentPlanMaximumEmployeeContribution
1.00
CY2014 hls Revolver Amounts Drawn
RevolverAmountsDrawn
325000000 USD
CY2015 hls Revolver Amounts Drawn
RevolverAmountsDrawn
130000000 USD
CY2012Q4 hls Self Insurance Reserves Netof Reinsurance Receivables
SelfInsuranceReservesNetofReinsuranceReceivables
118900000 USD
CY2013Q4 hls Self Insurance Reserves Netof Reinsurance Receivables
SelfInsuranceReservesNetofReinsuranceReceivables
107700000 USD
CY2014Q4 hls Self Insurance Reserves Netof Reinsurance Receivables
SelfInsuranceReservesNetofReinsuranceReceivables
108300000 USD
CY2015Q4 hls Self Insurance Reserves Netof Reinsurance Receivables
SelfInsuranceReservesNetofReinsuranceReceivables
115500000 USD
CY2013 hls Senior Management Bonus Program Total Costs
SeniorManagementBonusProgramTotalCosts
11500000 USD
CY2014 hls Senior Management Bonus Program Total Costs
SeniorManagementBonusProgramTotalCosts
9000000 USD
CY2015 hls Senior Management Bonus Program Total Costs
SeniorManagementBonusProgramTotalCosts
9100000 USD
CY2012Q4 hls Senior Notes Issuance Proceeds Used For Debt Reduction
SeniorNotesIssuanceProceedsUsedForDebtReduction
64500000 USD
CY2015Q4 hls Senior Notes Repurchase Price Change In Control
SeniorNotesRepurchasePriceChangeInControl
1.01
CY2015Q4 hls Seniorsecuredleverageratiomaximum
Seniorsecuredleverageratiomaximum
1.75
CY2015 hls Share Based Compensation Arrangement By Share Based Payment Awards Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardsOptionsExercisesInPeriodWeightedAverageExercisePrice
26.06
CY2015 hls Share Based Compensation Arrangement By Share Based Payment Awards Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardsOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.00
CY2015 hls Share Based Compensation Arrangement By Share Based Payment Awards Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardsOptionsForfeituresInPeriodWeightedAverageExercisePrice
24.85
CY2015 hls Share Based Compensation Arrangement By Share Based Payment Awards Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardsOptionsGrantsInPeriodWeightedAverageExercisePrice
43.14
CY2015 hls Sharebased Compensation Arrangementby Sharebased Payment Awards Options Exercisable Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementbySharebasedPaymentAwardsOptionsExercisableWeightedAverageRemainingContractualTerm
P3Y6M
CY2015 hls Stock Issued During Period Value Conversionof Preferred Stock
StockIssuedDuringPeriodValueConversionofPreferredStock
93200000 USD
CY2009Q3 hls Stock Warrants Issued Term
StockWarrantsIssuedTerm
7 Y
CY2014Q4 hls Termloanfacilitydraw
Termloanfacilitydraw
75000000 USD
CY2013 hls Treasury Stock Reacquired
TreasuryStockReacquired
5800000 USD
CY2014 hls Treasury Stock Reacquired
TreasuryStockReacquired
9700000 USD
CY2015 hls Treasury Stock Reacquired
TreasuryStockReacquired
17200000 USD
CY2013 hls Treasury Stock Value Acquired Cost Method Common Stock
TreasuryStockValueAcquiredCostMethodCommonStock
234100000 USD
CY2014 hls Treasury Stock Value Acquired Cost Method Common Stock
TreasuryStockValueAcquiredCostMethodCommonStock
43100000 USD
CY2015 hls Treasury Stock Value Acquired Cost Method Common Stock
TreasuryStockValueAcquiredCostMethodCommonStock
45300000 USD
CY2013 hls Treasury Stock Value Acquired Cost Method Preferred Stock
TreasuryStockValueAcquiredCostMethodPreferredStock
71600000 USD
CY2013 hls Undistributed Earnings From Discontinued Operations Allocatedto Participating Securities
UndistributedEarningsFromDiscontinuedOperationsAllocatedtoParticipatingSecurities
0 USD
CY2014 hls Undistributed Earnings From Discontinued Operations Allocatedto Participating Securities
UndistributedEarningsFromDiscontinuedOperationsAllocatedtoParticipatingSecurities
-100000 USD
CY2015 hls Undistributed Earnings From Discontinued Operations Allocatedto Participating Securities
UndistributedEarningsFromDiscontinuedOperationsAllocatedtoParticipatingSecurities
0 USD
CY2013 hls Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromPriorPeriodTaxPositions
0 USD
CY2014 hls Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromPriorPeriodTaxPositions
400000 USD
CY2013 hls Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities
0 USD
CY2013 hls Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedIncreasesResultingFromPriorPeriodTaxPositions
300000 USD
CY2014 hls Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedIncreasesResultingFromPriorPeriodTaxPositions
100000 USD
CY2015 hls Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedIncreasesResultingFromPriorPeriodTaxPositions
0 USD
CY2015 hls Unrecognized Tax Benefits Income Tax Penaltiesand Interest Accrued Increases Resultingfrom Current Period Tax Positions
UnrecognizedTaxBenefitsIncomeTaxPenaltiesandInterestAccruedIncreasesResultingfromCurrentPeriodTaxPositions
0 USD
CY2014Q4 hls Vehicles
Vehicles
9300000 USD
CY2015Q4 hls Vehicles
Vehicles
10000000 USD
CY2013 hls Warrants Exercised Value
WarrantsExercisedValue
15300000 USD
CY2014 hls Warrants Exercised Value
WarrantsExercisedValue
6300000 USD
CY2014Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
13900000 USD
CY2015Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
7200000 USD
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
53400000 USD
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
61600000 USD
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
323200000 USD
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
410500000 USD
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
784000000 USD
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
874300000 USD
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-500000 USD
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1200000 USD
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2810500000 USD
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2834900000 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
71000000 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24800000 USD
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23900000 USD
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22400000 USD
CY2013 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
87800000 USD
CY2014 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
168700000 USD
CY2015 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
231100000 USD
CY2013 us-gaap Advertising Expense
AdvertisingExpense
5200000 USD
CY2014 us-gaap Advertising Expense
AdvertisingExpense
5300000 USD
CY2015 us-gaap Advertising Expense
AdvertisingExpense
7300000 USD
CY2014Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
22200000 USD
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
39300000 USD
CY2014Q4 us-gaap Allowance For Doubtful Accounts Receivable Noncurrent
AllowanceForDoubtfulAccountsReceivableNoncurrent
20800000 USD
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable Noncurrent
AllowanceForDoubtfulAccountsReceivableNoncurrent
32300000 USD
CY2013 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
5000000 USD
CY2014 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
12700000 USD
CY2015 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
14300000 USD
CY2013 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17300000 USD
CY2014 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
20300000 USD
CY2015 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
36000000 USD
CY2013 us-gaap Amortization Of Leased Asset
AmortizationOfLeasedAsset
9500000 USD
CY2014 us-gaap Amortization Of Leased Asset
AmortizationOfLeasedAsset
7500000 USD
CY2015 us-gaap Amortization Of Leased Asset
AmortizationOfLeasedAsset
12700000 USD
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
100000 shares
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
100000 shares
CY2014Q4 us-gaap Assets
Assets
3388300000 USD
CY2015Q4 us-gaap Assets
Assets
4606100000 USD
CY2014Q4 us-gaap Assets Current
AssetsCurrent
686600000 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
598700000 USD
CY2014Q4 us-gaap Available For Sale Equity Securities Amortized Cost Basis
AvailableForSaleEquitySecuritiesAmortizedCostBasis
51300000 USD
CY2015Q4 us-gaap Available For Sale Equity Securities Amortized Cost Basis
AvailableForSaleEquitySecuritiesAmortizedCostBasis
58300000 USD
CY2015 us-gaap Available For Sale Securities Gross Realized Gains Losses Sale Proceeds
AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds
1200000 USD
CY2014 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
500000 USD
CY2015 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
300000 USD
CY2014 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
1300000 USD
CY2015 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
2400000 USD
CY2014Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
1214400000 USD
CY2015Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
1521100000 USD
CY2013 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
311300000 USD
CY2014 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
237500000 USD
CY2013 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
2627600000 USD
CY2014 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
2799800000 USD
us-gaap Business Combination Pro Forma Information Earnings Or Loss Of Acquiree Since Acquisition Date Actual
BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
4000000 USD
us-gaap Business Combination Pro Forma Information Revenue Of Acquiree Since Acquisition Date Actual
BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
27200000 USD
CY2015Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
42600000 USD
CY2015Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
2800000 USD
CY2015Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
25700000 USD
CY2014Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Long Term Debt
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt
2900000 USD
CY2015Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Long Term Debt
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt
1300000 USD
CY2015Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
220600000 USD
CY2015Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
771400000 USD
CY2013 us-gaap Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain
BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
0 USD
CY2014 us-gaap Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain
BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
27200000 USD
CY2015 us-gaap Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain
BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
0 USD
CY2014Q4 us-gaap Capital Lease Obligations
CapitalLeaseObligations
86700000 USD
CY2015Q4 us-gaap Capital Lease Obligations
CapitalLeaseObligations
288200000 USD
CY2014Q4 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
129800000 USD
CY2015Q4 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
340700000 USD
CY2014Q4 us-gaap Capital Leases Balance Sheet Assets By Major Class Net
CapitalLeasesBalanceSheetAssetsByMajorClassNet
74600000 USD
CY2015Q4 us-gaap Capital Leases Balance Sheet Assets By Major Class Net
CapitalLeasesBalanceSheetAssetsByMajorClassNet
274100000 USD
CY2015Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
543100000 USD
CY2015Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
32800000 USD
CY2015Q4 us-gaap Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
27800000 USD
CY2015Q4 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
30300000 USD
CY2012Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10000000 shares
CY2014Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2900000 shares
CY2004Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10000000 shares
CY2014Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0 shares
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q4 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
33400000 USD
CY2015Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
34100000 USD
CY2015Q4 us-gaap Capital Leases Future Minimum Payments Due Thereafter
CapitalLeasesFutureMinimumPaymentsDueThereafter
384700000 USD
CY2015Q4 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
254900000 USD
CY2015Q4 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
288200000 USD
CY2014Q4 us-gaap Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
55200000 USD
CY2015Q4 us-gaap Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
66600000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
132800000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64500000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66700000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61600000 USD
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-68300000 USD
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2200000 USD
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5100000 USD
CY2013 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
3300000 USD
CY2014 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
0 USD
CY2015 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
500000 USD
CY2013 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-1900000 USD
CY2014 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-1200000 USD
CY2015 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-700000 USD
CY2006Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2000000 shares
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q1 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.18
CY2013Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.18
CY2014Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.21
CY2015Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.23
CY2013 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.36
CY2014 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.78
CY2015 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.88
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
104058832 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
108275900 shares
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
1000000 USD
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
1100000 USD
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
322100000 USD
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
221600000 USD
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
182400000 USD
CY2013 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
57800000 USD
CY2014 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
59700000 USD
CY2015 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
69700000 USD
CY2013 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
379900000 USD
CY2014 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
281300000 USD
CY2015 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
252100000 USD
CY2014Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
28600000 USD
CY2015Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
51100000 USD
CY2014Q4 us-gaap Construction Payable Current And Noncurrent
ConstructionPayableCurrentAndNoncurrent
10300000 USD
CY2015Q4 us-gaap Construction Payable Current And Noncurrent
ConstructionPayableCurrentAndNoncurrent
9600000 USD
CY2013 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 USD
CY2014 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 USD
CY2015 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
93200000 USD
CY2006Q1 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
32.7869 shares
CY2015 us-gaap Convertible Preferred Stock Terms Of Conversion
ConvertiblePreferredStockTermsOfConversion
We may at any time cause the shares of preferred stock to be automatically converted into shares of our common stock at the conversion rate then in effect if the closing sale price of our common stock for 20 trading days within a period of 30 consecutive trading days ending on the trading day before the date we give the notice of forced conversion exceeds 150% of the conversion price of the preferred stock. If we are subject to a fundamental change, as defined in the certificate of designation of the preferred stock, each holder of shares of preferred stock has the right, subject to certain limitations, to require us to purchase with cash any or all of its shares of preferred stock at a purchase price equal to 100% of the accreted liquidation preference, plus any accrued and unpaid dividends to the date of purchase. In addition, if holders of the preferred stock elect to convert shares of preferred stock in connection with certain fundamental changes, we will in certain circumstances increase the conversion rate for such shares of preferred stock.
CY2014Q4 us-gaap Cost Method Investments
CostMethodInvestments
1200000 USD
CY2015Q4 us-gaap Cost Method Investments
CostMethodInvestments
300000 USD
CY2013 us-gaap Costs And Expenses
CostsAndExpenses
1764900000 USD
CY2014 us-gaap Costs And Expenses
CostsAndExpenses
1906900000 USD
CY2015 us-gaap Costs And Expenses
CostsAndExpenses
2569000000 USD
CY2013 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
900000 USD
CY2014 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
2500000 USD
CY2015 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
2600000 USD
CY2013 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
6300000 USD
CY2014 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
13300000 USD
CY2015 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
14800000 USD
CY2013 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
5400000 USD
CY2014 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
10800000 USD
CY2015 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
12200000 USD
CY2014Q4 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
2111200000 USD
CY2015Q4 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
3171500000 USD
CY2010Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
525000000 USD
CY2012Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
275000000 USD
CY2014 us-gaap Debt Issuance Costs
DebtIssuanceCosts
20400000 USD
CY2013 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
11300000 USD
CY2014 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
95300000 USD
CY2015 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
113900000 USD
CY2013 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
6400000 USD
CY2014 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
97400000 USD
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
127100000 USD
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
14600000 USD
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
11800000 USD
CY2013 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-4900000 USD
CY2014 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
2100000 USD
CY2015 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
13200000 USD
CY2014Q4 us-gaap Deferred Tax Assets Equity Method Investments
DeferredTaxAssetsEquityMethodInvestments
23800000 USD
CY2015Q4 us-gaap Deferred Tax Assets Equity Method Investments
DeferredTaxAssetsEquityMethodInvestments
22100000 USD
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
475700000 USD
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
367000000 USD
CY2014Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
317800000 USD
CY2015Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
190800000 USD
CY2014Q4 us-gaap Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
-188400000 USD
CY2015Q4 us-gaap Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
0 USD
CY2014Q4 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
129400000 USD
CY2015Q4 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
190800000 USD
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
452700000 USD
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
339400000 USD
CY2014Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
188400000 USD
CY2015Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
0 USD
CY2014Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
129400000 USD
CY2015Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
190800000 USD
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
301300000 USD
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
161100000 USD
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1600000 USD
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
800000 USD
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
9900000 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
14000000 USD
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Alternative Minimum Tax
DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax
10500000 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Alternative Minimum Tax
DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax
10600000 USD
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
23700000 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
23400000 USD
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
18000000 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
24500000 USD
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
20600000 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
25700000 USD
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Self Insurance
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance
25600000 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Self Insurance
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance
26000000 USD
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
23000000 USD
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
27600000 USD
CY2014Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
134900000 USD
CY2015Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
148600000 USD
CY2014Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
97500000 USD
CY2015Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
112800000 USD
CY2014Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
5700000 USD
CY2015Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
500000 USD
CY2013 us-gaap Depreciation
Depreciation
67900000 USD
CY2014 us-gaap Depreciation
Depreciation
79900000 USD
CY2015 us-gaap Depreciation
Depreciation
91000000 USD
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
94700000 USD
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
107700000 USD
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
139700000 USD
CY2014Q4 us-gaap Derivative Assets Noncurrent
DerivativeAssetsNoncurrent
9900000 USD
CY2014 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
9900000 USD
CY2015 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
2000000 USD
CY2013 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
32000000 USD
CY2014 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
69000000 USD
CY2015 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
79900000 USD
CY2013 us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
21000000 USD
CY2014 us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
6300000 USD
CY2015 us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
1600000 USD
CY2014Q4 us-gaap Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
0 USD
CY2015Q4 us-gaap Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
0 USD
CY2014Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
0 USD
CY2015Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
0 USD
CY2013 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.58
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.51
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.93
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.55
CY2014Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.46
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.46
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.47
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.47
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.56
CY2015Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.52
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.02
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
2.58
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
2.46
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
2.02
CY2013 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.58
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.48
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.85
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.52
CY2014Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.44
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.29
CY2015Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.44
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.45
CY2015Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.52
CY2015Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.49
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.91
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.032
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.286
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.359
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.023
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.019
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.012
CY2013 us-gaap Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary
EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
0.000
CY2014 us-gaap Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary
EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
-0.036
CY2015 us-gaap Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary
EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
0.000
CY2013 us-gaap Effective Income Tax Rate Reconciliation Minority Interest Income Expense
EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense
-0.051
CY2014 us-gaap Effective Income Tax Rate Reconciliation Minority Interest Income Expense
EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense
-0.051
CY2015 us-gaap Effective Income Tax Rate Reconciliation Minority Interest Income Expense
EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense
-0.053
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.003
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.013
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.040
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.043
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.036
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements
EffectiveIncomeTaxRateReconciliationTaxSettlements
-0.287
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements
EffectiveIncomeTaxRateReconciliationTaxSettlements
0.000
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements
EffectiveIncomeTaxRateReconciliationTaxSettlements
0.001
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
123300000 USD
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
126200000 USD
CY2015 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
14600000 USD
CY2014Q4 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
800000 USD
CY2015Q4 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
900000 USD
CY2013 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
11400000 USD
CY2014 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
12600000 USD
CY2015 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
7700000 USD
CY2014Q4 us-gaap Equity Method Investment Summarized Financial Information Assets
EquityMethodInvestmentSummarizedFinancialInformationAssets
22700000 USD
CY2015Q4 us-gaap Equity Method Investment Summarized Financial Information Assets
EquityMethodInvestmentSummarizedFinancialInformationAssets
28300000 USD
CY2014Q4 us-gaap Equity Method Investment Summarized Financial Information Current Assets
EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets
9600000 USD
CY2015Q4 us-gaap Equity Method Investment Summarized Financial Information Current Assets
EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets
7800000 USD
CY2014Q4 us-gaap Equity Method Investment Summarized Financial Information Current Liabilities
EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities
700000 USD
CY2015Q4 us-gaap Equity Method Investment Summarized Financial Information Current Liabilities
EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities
1400000 USD
CY2013 us-gaap Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items
EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems
24600000 USD
CY2014 us-gaap Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items
EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems
30900000 USD
CY2015 us-gaap Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items
EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems
18900000 USD
CY2014Q4 us-gaap Equity Method Investment Summarized Financial Information Liabilities And Equity
EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity
22700000 USD
CY2015Q4 us-gaap Equity Method Investment Summarized Financial Information Liabilities And Equity
EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity
28300000 USD
CY2014Q4 us-gaap Equity Method Investment Summarized Financial Information Minority Interest
EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest
13700000 USD
CY2015Q4 us-gaap Equity Method Investment Summarized Financial Information Minority Interest
EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest
15400000 USD
CY2013 us-gaap Equity Method Investment Summarized Financial Information Net Income Loss
EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss
24600000 USD
CY2014 us-gaap Equity Method Investment Summarized Financial Information Net Income Loss
EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss
30900000 USD
CY2015 us-gaap Equity Method Investment Summarized Financial Information Net Income Loss
EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss
18900000 USD
CY2014Q4 us-gaap Equity Method Investment Summarized Financial Information Noncurrent Assets
EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets
13100000 USD
CY2015Q4 us-gaap Equity Method Investment Summarized Financial Information Noncurrent Assets
EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets
20500000 USD
CY2014Q4 us-gaap Equity Method Investment Summarized Financial Information Noncurrent Liabilities
EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities
100000 USD
CY2015Q4 us-gaap Equity Method Investment Summarized Financial Information Noncurrent Liabilities
EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities
100000 USD
CY2013 us-gaap Equity Method Investment Summarized Financial Information Revenue
EquityMethodInvestmentSummarizedFinancialInformationRevenue
74300000 USD
CY2014 us-gaap Equity Method Investment Summarized Financial Information Revenue
EquityMethodInvestmentSummarizedFinancialInformationRevenue
50200000 USD
CY2015 us-gaap Equity Method Investment Summarized Financial Information Revenue
EquityMethodInvestmentSummarizedFinancialInformationRevenue
36500000 USD
CY2014Q4 us-gaap Equity Method Investment Underlying Equity In Net Assets
EquityMethodInvestmentUnderlyingEquityInNetAssets
8200000 USD
CY2015Q4 us-gaap Equity Method Investment Underlying Equity In Net Assets
EquityMethodInvestmentUnderlyingEquityInNetAssets
11400000 USD
CY2014Q4 us-gaap Equity Method Investments
EquityMethodInvestments
8200000 USD
CY2015Q4 us-gaap Equity Method Investments
EquityMethodInvestments
11400000 USD
CY2014Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
172400000 USD
CY2015Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
208400000 USD
CY2015Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
45400000 USD
CY2015Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
23300000 USD
CY2012Q4 us-gaap Goodwill
Goodwill
437300000 USD
CY2015Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
26800000 USD
CY2015Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
30300000 USD
CY2015Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
38700000 USD
CY2014Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
478500000 USD
CY2015Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
627800000 USD
CY2014Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
306100000 USD
CY2015Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
419400000 USD
CY2014Q4 us-gaap Fixtures And Equipment Gross
FixturesAndEquipmentGross
364200000 USD
CY2015Q4 us-gaap Fixtures And Equipment Gross
FixturesAndEquipmentGross
392700000 USD
CY2013 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
-5900000 USD
CY2014 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
-6700000 USD
CY2015 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
-2600000 USD
CY2013 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2400000 USD
CY2014 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-13200000 USD
CY2015Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1200000 USD
CY2015Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-18800000 USD
CY2015Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2400000 USD
CY2015 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-22400000 USD
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
119100000 USD
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
124800000 USD
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
133300000 USD
CY2013Q4 us-gaap Goodwill
Goodwill
456900000 USD
CY2014Q4 us-gaap Goodwill
Goodwill
1084000000 USD
CY2015Q4 us-gaap Goodwill
Goodwill
1890100000 USD
CY2013 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
13700000 USD
CY2014 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
593100000 USD
CY2015 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
806100000 USD
CY2015Q4 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
0 USD
CY2013 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2014 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2015 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2013 us-gaap Goodwill Written Off Related To Sale Of Business Unit
GoodwillWrittenOffRelatedToSaleOfBusinessUnit
300000 USD
CY2013 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
2273200000 USD
CY2014Q1 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
591200000 USD
CY2014Q2 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
604400000 USD
CY2014Q3 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
596900000 USD
CY2014Q4 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
613400000 USD
CY2014 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
2405900000 USD
CY2015Q1 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
740600000 USD
CY2015Q2 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
764400000 USD
CY2015Q3 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
778600000 USD
CY2015Q4 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
879300000 USD
CY2015 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
3162900000 USD
CY2013 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
324700000 USD
CY2014Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.89
CY2014Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.56
CY2014 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
216500000 USD
CY2015 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
184000000 USD
CY2013 us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
57800000 USD
CY2014 us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
59700000 USD
CY2015 us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
69700000 USD
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
395200000 USD
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
386900000 USD
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
395600000 USD
CY2013 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
382500000 USD
CY2014Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
61600000 USD
CY2014Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
94100000 USD
CY2014Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
65700000 USD
CY2014Q4 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
54800000 USD
CY2014 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
276200000 USD
CY2015Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
59300000 USD
CY2015Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
61800000 USD
CY2015Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
67500000 USD
CY2015Q4 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
65100000 USD
CY2015 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
253700000 USD
CY2013 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
2.59
CY2014Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.51
CY2014Q4 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.43
CY2014 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
2.40
CY2015Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.47
CY2015Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.49
CY2015Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.56
CY2015Q4 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.51
CY2015 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
2.03
CY2013 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
2.59
CY2014Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.48
CY2014Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.81
CY2014Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.53
CY2014Q4 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.41
CY2014 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
2.24
CY2015Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.44
CY2015Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.47
CY2015Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.52
CY2015Q4 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.48
CY2015 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
1.92
CY2013 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-1100000 USD
CY2014Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-100000 USD
CY2014Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
3800000 USD
CY2014Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-900000 USD
CY2014Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
2700000 USD
CY2014Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.00
CY2014 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
5500000 USD
CY2015Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-300000 USD
CY2015Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-1600000 USD
CY2015Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
300000 USD
CY2015Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
700000 USD
CY2015 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-900000 USD
CY2013 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-1100000 USD
CY2014 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
5500000 USD
CY2015 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-900000 USD
CY2013 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.01
CY2014Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.00
CY2014Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.04
CY2014Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.01
CY2014Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.03
CY2014 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.06
CY2015Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.00
CY2015Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.02
CY2015Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.00
CY2015Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.01
CY2015 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.01
CY2013 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.01
CY2014Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.04
CY2014Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.01
CY2014Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.03
CY2014 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.05
CY2015Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.00
CY2015Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.02
CY2015Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.00
CY2015Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.01
CY2015 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.01
CY2013 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
11200000 USD
CY2014 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
10700000 USD
CY2015 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
8700000 USD
CY2013 us-gaap Income Tax Effects Allocated Directly To Equity
IncomeTaxEffectsAllocatedDirectlyToEquity
2900000 USD
CY2014 us-gaap Income Tax Effects Allocated Directly To Equity
IncomeTaxEffectsAllocatedDirectlyToEquity
-1800000 USD
CY2015 us-gaap Income Tax Effects Allocated Directly To Equity
IncomeTaxEffectsAllocatedDirectlyToEquity
-11700000 USD
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12700000 USD
CY2014Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
32800000 USD
CY2014Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
36500000 USD
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
22100000 USD
CY2014Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
19300000 USD
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
110700000 USD
CY2015Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
30300000 USD
CY2015Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
32200000 USD
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
35900000 USD
CY2015Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
43500000 USD
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
141900000 USD
CY2013 us-gaap Income Taxes Paid
IncomeTaxesPaid
12500000 USD
CY2014 us-gaap Income Taxes Paid
IncomeTaxesPaid
17700000 USD
CY2015 us-gaap Income Taxes Paid
IncomeTaxesPaid
16800000 USD
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6400000 USD
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5400000 USD
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
900000 USD
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
55100000 USD
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
91600000 USD
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
134100000 USD
CY2015 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0 USD
CY2013 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
4600000 USD
CY2014 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-10400000 USD
CY2015 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-4300000 USD
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4800000 USD
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-6500000 USD
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
9600000 USD
CY2013 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
3100000 USD
CY2014 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-6800000 USD
CY2015 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-2700000 USD
CY2013 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
1000000 shares
CY2014 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
8200000 shares
CY2015 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
8300000 shares
CY2013 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
10500000 shares
CY2014 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
3200000 shares
CY2015 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
1000000 shares
CY2013 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2500000 shares
CY2014 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2500000 shares
CY2015 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2300000 shares
CY2014Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
306100000 USD
CY2015Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
419400000 USD
CY2013 us-gaap Interest And Debt Expense
InterestAndDebtExpense
100400000 USD
CY2014 us-gaap Interest And Debt Expense
InterestAndDebtExpense
109200000 USD
CY2015 us-gaap Interest And Debt Expense
InterestAndDebtExpense
142900000 USD
CY2013 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
1900000 USD
CY2014 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
1500000 USD
CY2015 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
1300000 USD
CY2013 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
1000000 USD
CY2014 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
9000000 USD
CY2015 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
9400000 USD
CY2013 us-gaap Interest Paid
InterestPaid
99400000 USD
CY2014 us-gaap Interest Paid
InterestPaid
100600000 USD
CY2015 us-gaap Interest Paid
InterestPaid
121400000 USD
CY2014Q4 us-gaap Interest Payable Current
InterestPayableCurrent
21200000 USD
CY2015Q4 us-gaap Interest Payable Current
InterestPayableCurrent
29700000 USD
CY2014Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
9400000 USD
CY2014Q4 us-gaap Line Of Credit Facility Interest Rate At Period End
LineOfCreditFacilityInterestRateAtPeriodEnd
0.020
CY2015Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
11700000 USD
CY2013 us-gaap Labor And Related Expense
LaborAndRelatedExpense
1089700000 USD
CY2014 us-gaap Labor And Related Expense
LaborAndRelatedExpense
1161700000 USD
CY2015 us-gaap Labor And Related Expense
LaborAndRelatedExpense
1670800000 USD
CY2014Q4 us-gaap Land
Land
108100000 USD
CY2015Q4 us-gaap Land
Land
113300000 USD
CY2014Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
79100000 USD
CY2015Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
96200000 USD
CY2014Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
31800000 USD
CY2015Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
34200000 USD
CY2014Q4 us-gaap Liabilities
Liabilities
2590900000 USD
CY2015Q4 us-gaap Liabilities
Liabilities
3705700000 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3388300000 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4606100000 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
364300000 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
426400000 USD
CY2014Q4 us-gaap Line Of Credit
LineOfCredit
325000000 USD
CY2015Q4 us-gaap Line Of Credit
LineOfCredit
130000000 USD
CY2015Q4 us-gaap Line Of Credit Facility Interest Rate At Period End
LineOfCreditFacilityInterestRateAtPeriodEnd
0.023
CY2014Q4 us-gaap Loans Payable To Bank
LoansPayableToBank
447500000 USD
CY2015Q4 us-gaap Loans Payable To Bank
LoansPayableToBank
443300000 USD
CY2014Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
2090400000 USD
CY2015Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
3134700000 USD
CY2014Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
20800000 USD
CY2015Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
36800000 USD
CY2013 us-gaap Management Fees Revenue
ManagementFeesRevenue
0 USD
CY2014 us-gaap Management Fees Revenue
ManagementFeesRevenue
0 USD
CY2015 us-gaap Management Fees Revenue
ManagementFeesRevenue
0 USD
CY2014Q4 us-gaap Marketable Securities Restricted
MarketableSecuritiesRestricted
50500000 USD
CY2015Q4 us-gaap Marketable Securities Restricted
MarketableSecuritiesRestricted
56200000 USD
CY2014Q4 us-gaap Marketable Securities Restricted Noncurrent
MarketableSecuritiesRestrictedNoncurrent
45900000 USD
CY2015Q4 us-gaap Marketable Securities Restricted Noncurrent
MarketableSecuritiesRestrictedNoncurrent
40100000 USD
CY2015Q4 us-gaap Minimum Lease Payments Sale Leaseback Transactions Thereafter
MinimumLeasePaymentsSaleLeasebackTransactionsThereafter
8300000 USD
CY2015Q4 us-gaap Minimum Lease Payments Sale Leaseback Transactions Within Five Years
MinimumLeasePaymentsSaleLeasebackTransactionsWithinFiveYears
2700000 USD
CY2015Q4 us-gaap Minimum Lease Payments Sale Leaseback Transactions Within Four Years
MinimumLeasePaymentsSaleLeasebackTransactionsWithinFourYears
2700000 USD
CY2015Q4 us-gaap Minimum Lease Payments Sale Leaseback Transactions Within One Year
MinimumLeasePaymentsSaleLeasebackTransactionsWithinOneYear
2700000 USD
CY2015Q4 us-gaap Minimum Lease Payments Sale Leaseback Transactions Within Three Years
MinimumLeasePaymentsSaleLeasebackTransactionsWithinThreeYears
2700000 USD
CY2015Q4 us-gaap Minimum Lease Payments Sale Leaseback Transactions Within Two Years
MinimumLeasePaymentsSaleLeasebackTransactionsWithinTwoYears
2700000 USD
CY2014Q4 us-gaap Minority Interest
MinorityInterest
146300000 USD
CY2015Q4 us-gaap Minority Interest
MinorityInterest
167900000 USD
CY2015 us-gaap Minority Interest Change In Redemption Value
MinorityInterestChangeInRedemptionValue
-18200000 USD
CY2013 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
40400000 USD
CY2014 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
44900000 USD
CY2015 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
49000000 USD
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-312400000 USD
CY2014 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
434200000 USD
CY2015 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
639900000 USD
CY2013 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-226200000 USD
CY2014 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-876900000 USD
CY2015 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1129800000 USD
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
470300000 USD
CY2014 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
444900000 USD
CY2015 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
484800000 USD
CY2013 us-gaap Net Income Loss
NetIncomeLoss
323600000 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
46700000 USD
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
83100000 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
50100000 USD
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
42100000 USD
CY2014 us-gaap Net Income Loss
NetIncomeLoss
222000000 USD
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
42500000 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
42900000 USD
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
50700000 USD
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
47000000 USD
CY2015 us-gaap Net Income Loss
NetIncomeLoss
183100000 USD
CY2013 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
57800000 USD
CY2014Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
14800000 USD
CY2014Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
14800000 USD
CY2014Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
14700000 USD
CY2014Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
15400000 USD
CY2014 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
59700000 USD
CY2015Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
16500000 USD
CY2015Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
17300000 USD
CY2015Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
17100000 USD
CY2015Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
18800000 USD
CY2015 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
69700000 USD
CY2013 us-gaap Net Income Loss Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
52000000 USD
CY2014 us-gaap Net Income Loss Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
53100000 USD
CY2015 us-gaap Net Income Loss Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
55900000 USD
CY2013 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
5800000 USD
CY2014 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
6600000 USD
CY2015 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
13800000 USD
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
231000000 USD
CY2014 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
215700000 USD
CY2015 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
181500000 USD
CY2013 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
324600000 USD
CY2014 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
231000000 USD
CY2015 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
192500000 USD
CY2013 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
375600000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
52100000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
156200000 USD
CY2014 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
275100000 USD
CY2015 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
239000000 USD
CY2014 us-gaap Noncontrolling Interest Increase From Business Combination
NoncontrollingInterestIncreaseFromBusinessCombination
14000000 USD
CY2014Q4 us-gaap Notes Payable Related Parties Current And Noncurrent
NotesPayableRelatedPartiesCurrentAndNoncurrent
0 USD
CY2015Q4 us-gaap Notes Payable Related Parties Current And Noncurrent
NotesPayableRelatedPartiesCurrentAndNoncurrent
0 USD
CY2014Q4 us-gaap Notes Receivable Related Parties Noncurrent
NotesReceivableRelatedPartiesNoncurrent
0 USD
CY2015Q4 us-gaap Notes Receivable Related Parties Noncurrent
NotesReceivableRelatedPartiesNoncurrent
0 USD
CY2015Q4 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
34
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
387600000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
59200000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals
OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals
13500000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
32900000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
41200000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
46000000 USD
CY2013 us-gaap Operating Leases Income Statement Sublease Revenue
OperatingLeasesIncomeStatementSubleaseRevenue
4900000 USD
CY2014 us-gaap Operating Leases Income Statement Sublease Revenue
OperatingLeasesIncomeStatementSubleaseRevenue
5100000 USD
CY2015 us-gaap Operating Leases Income Statement Sublease Revenue
OperatingLeasesIncomeStatementSubleaseRevenue
5000000 USD
CY2013 us-gaap Operating Leases Rent Expense Contingent Rentals
OperatingLeasesRentExpenseContingentRentals
20300000 USD
CY2014 us-gaap Operating Leases Rent Expense Contingent Rentals
OperatingLeasesRentExpenseContingentRentals
18200000 USD
CY2015 us-gaap Operating Leases Rent Expense Contingent Rentals
OperatingLeasesRentExpenseContingentRentals
21600000 USD
CY2013 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
40300000 USD
CY2014 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
37300000 USD
CY2015 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
48800000 USD
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
64800000 USD
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
59400000 USD
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
74200000 USD
CY2015Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
261600000 USD
CY2015 us-gaap Origination Of Notes Receivable From Related Parties
OriginationOfNotesReceivableFromRelatedParties
0 USD
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
162500000 USD
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
197000000 USD
CY2013 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-1600000 USD
CY2014 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-700000 USD
CY2015 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-1300000 USD
CY2013 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1500000 USD
CY2014 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-400000 USD
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-700000 USD
CY2013 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
900000 USD
CY2014 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
500000 USD
CY2015 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
1200000 USD
CY2013 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-100000 USD
CY2014 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-300000 USD
CY2015 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-600000 USD
CY2013 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-700000 USD
CY2014 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-200000 USD
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-100000 USD
CY2013 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
323000000 USD
CY2014 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
351600000 USD
CY2015 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
432100000 USD
CY2013 us-gaap Other Expenses
OtherExpenses
200000 USD
CY2014 us-gaap Other Expenses
OtherExpenses
0 USD
CY2015 us-gaap Other Expenses
OtherExpenses
0 USD
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
145600000 USD
CY2015Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
172100000 USD
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
37500000 USD
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
43000000 USD
CY2013 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-4300000 USD
CY2014 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-4800000 USD
CY2015 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
600000 USD
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4500000 USD
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
31200000 USD
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5500000 USD
CY2014Q4 us-gaap Other Notes Payable
OtherNotesPayable
41500000 USD
CY2015Q4 us-gaap Other Notes Payable
OtherNotesPayable
39200000 USD
CY2013 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0 USD
CY2014 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0 USD
CY2015 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0 USD
CY2015 us-gaap Partners Capital Account Contributions
PartnersCapitalAccountContributions
14800000 USD
CY2013 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-500000 USD
CY2014 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-2200000 USD
CY2015 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-2700000 USD
CY2013 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
234100000 USD
CY2014 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
43100000 USD
CY2015 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
45300000 USD
CY2013 us-gaap Payments For Software
PaymentsForSoftware
21300000 USD
CY2014 us-gaap Payments For Software
PaymentsForSoftware
17000000 USD
CY2015 us-gaap Payments For Software
PaymentsForSoftware
28100000 USD
CY2013 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
2600000 USD
CY2014 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
6500000 USD
CY2015 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
31900000 USD
CY2013 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
15700000 USD
CY2014 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
65800000 USD
CY2015 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
77200000 USD
CY2013 us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
46300000 USD
CY2014 us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
54100000 USD
CY2015 us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
54400000 USD
CY2013 us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
23000000 USD
CY2014 us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
6300000 USD
CY2015 us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
3100000 USD
CY2013 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
28900000 USD
CY2014 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
694800000 USD
CY2015 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
985100000 USD
CY2013Q4 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.0650
CY2015 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.0650
CY2013 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
21000000 USD
CY2014 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6300000 USD
CY2015 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1600000 USD
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
195200000 USD
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
170900000 USD
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
128400000 USD
CY2013 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
9200000 USD
CY2014 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
3500000 USD
CY2015 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
7100000 USD
CY2013 us-gaap Preferred Stock Redemption Premium
PreferredStockRedemptionPremium
71600000 USD
CY2014 us-gaap Preferred Stock Redemption Premium
PreferredStockRedemptionPremium
0 USD
CY2015 us-gaap Preferred Stock Redemption Premium
PreferredStockRedemptionPremium
0 USD
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
62700000 USD
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
80700000 USD
CY2014 us-gaap Prior Period Reclassification Adjustment
PriorPeriodReclassificationAdjustment
-64300000 USD
CY2015 us-gaap Prior Period Reclassification Adjustment
PriorPeriodReclassificationAdjustment
-71300000 USD
CY2013 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
4800000 USD
CY2014 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
1300000 USD
CY2015 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
7400000 USD
CY2013 us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
0 USD
CY2014 us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
450000000 USD
CY2015 us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
250000000 USD
CY2013 us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
0 USD
CY2014 us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
175000000 USD
CY2015 us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
1400000000 USD
CY2013 us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
197000000 USD
CY2014 us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
440000000 USD
CY2015 us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
540000000 USD
CY2013 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
15200000 USD
CY2014 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
CY2015 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
CY2013 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
6400000 USD
CY2014 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
7400000 USD
CY2015 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
5200000 USD
CY2013 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
0 USD
CY2014 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
0 USD
CY2015 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
0 USD
CY2013 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0 USD
CY2014 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0 USD
CY2015 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
12800000 USD
CY2013Q3 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
10800000 USD
CY2013 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
10800000 USD
CY2014 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
CY2014 us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
300000 USD
CY2013 us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
16900000 USD
CY2015 us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
200000 USD
CY2014Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
6300000 USD
CY2013 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
15300000 USD
CY2014 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
6300000 USD
CY2015 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2013 us-gaap Profit Loss
ProfitLoss
381400000 USD
CY2014Q1 us-gaap Profit Loss
ProfitLoss
61500000 USD
CY2014Q2 us-gaap Profit Loss
ProfitLoss
97900000 USD
CY2014Q3 us-gaap Profit Loss
ProfitLoss
64800000 USD
CY2014Q4 us-gaap Profit Loss
ProfitLoss
57500000 USD
CY2014 us-gaap Profit Loss
ProfitLoss
281700000 USD
CY2015Q1 us-gaap Profit Loss
ProfitLoss
59000000 USD
CY2015Q2 us-gaap Profit Loss
ProfitLoss
60200000 USD
CY2015Q3 us-gaap Profit Loss
ProfitLoss
67800000 USD
CY2015Q4 us-gaap Profit Loss
ProfitLoss
65800000 USD
CY2015 us-gaap Profit Loss
ProfitLoss
252800000 USD
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1775100000 USD
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2133300000 USD
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1019700000 USD
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1310100000 USD
CY2013 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
26000000 USD
CY2014 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
31600000 USD
CY2015 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
47200000 USD
CY2014Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
84700000 USD
CY2015Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
121100000 USD
CY2014Q4 us-gaap Redeemable Noncontrolling Interest Equity Fair Value
RedeemableNoncontrollingInterestEquityFairValue
84700000 USD
CY2015Q4 us-gaap Redeemable Noncontrolling Interest Equity Fair Value
RedeemableNoncontrollingInterestEquityFairValue
121100000 USD
CY2012Q4 us-gaap Reinsurance Receivables Paid Losses Recoverable
ReinsuranceReceivablesPaidLossesRecoverable
29400000 USD
CY2013Q4 us-gaap Reinsurance Receivables Paid Losses Recoverable
ReinsuranceReceivablesPaidLossesRecoverable
32600000 USD
CY2014Q4 us-gaap Reinsurance Receivables Paid Losses Recoverable
ReinsuranceReceivablesPaidLossesRecoverable
26000000 USD
CY2015Q4 us-gaap Reinsurance Receivables Paid Losses Recoverable
ReinsuranceReceivablesPaidLossesRecoverable
26600000 USD
CY2015 us-gaap Repayment Of Notes Receivable From Related Parties
RepaymentOfNotesReceivableFromRelatedParties
0 USD
CY2013 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
10100000 USD
CY2014 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
6100000 USD
CY2015 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
11000000 USD
CY2013 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
62500000 USD
CY2014 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
302600000 USD
CY2015 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
597400000 USD
CY2013 us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
152000000 USD
CY2014 us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
160000000 USD
CY2015 us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
735000000 USD
CY2015 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 USD
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
45600000 USD
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
45900000 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1879100000 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1696000000 USD
CY2014Q4 us-gaap Sale Leaseback Transaction Amount Due Under Financing Arrangement
SaleLeasebackTransactionAmountDueUnderFinancingArrangement
28000000 USD
CY2015Q4 us-gaap Sale Leaseback Transaction Amount Due Under Financing Arrangement
SaleLeasebackTransactionAmountDueUnderFinancingArrangement
28000000 USD
CY2012Q4 us-gaap Self Insurance Reserve
SelfInsuranceReserve
148300000 USD
CY2013Q4 us-gaap Self Insurance Reserve
SelfInsuranceReserve
140300000 USD
CY2014Q4 us-gaap Self Insurance Reserve
SelfInsuranceReserve
134300000 USD
CY2015Q4 us-gaap Self Insurance Reserve
SelfInsuranceReserve
142100000 USD
CY2014Q4 us-gaap Self Insurance Reserve Current
SelfInsuranceReserveCurrent
35600000 USD
CY2015Q4 us-gaap Self Insurance Reserve Current
SelfInsuranceReserveCurrent
40500000 USD
CY2014Q4 us-gaap Self Insurance Reserve Noncurrent
SelfInsuranceReserveNoncurrent
98700000 USD
CY2015Q4 us-gaap Self Insurance Reserve Noncurrent
SelfInsuranceReserveNoncurrent
101600000 USD
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
24800000 USD
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
23900000 USD
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
26200000 USD
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.021
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.021
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.014
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.022
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.019
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.418
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.403
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.395
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1811000 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
19.47
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
8200000 USD
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
7400000 USD
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2300000 USD
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2000 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
108000 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
28500000 USD
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2207000 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2056000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.85
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
21.37
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y2M
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y2M
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y8M12D
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
27800000 USD
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y1M6D
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
257000 shares
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
473200000 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
611400000 USD
CY2014 us-gaap Stockholders Equity Other
StockholdersEquityOther
2900000 USD
CY2012Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
403500000 USD
CY2013Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
468700000 USD
CY2014Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
619500000 USD
CY2015Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
779300000 USD
CY2013 us-gaap Stockholders Equity Other
StockholdersEquityOther
-3200000 USD
CY2015 us-gaap Stockholders Equity Other
StockholdersEquityOther
700000 USD
CY2013 us-gaap Supplies Expense
SuppliesExpense
105400000 USD
CY2014 us-gaap Supplies Expense
SuppliesExpense
111900000 USD
CY2015 us-gaap Supplies Expense
SuppliesExpense
128700000 USD
CY2014Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
93200000 USD
CY2015Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 USD
CY2014Q4 us-gaap Temporary Equity Liquidation Preference Per Share
TemporaryEquityLiquidationPreferencePerShare
1000
CY2015Q4 us-gaap Temporary Equity Liquidation Preference Per Share
TemporaryEquityLiquidationPreferencePerShare
0
CY2014Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.10
CY2015Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.00
CY2014Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
1500000 shares
CY2015Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0 shares
CY2014Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
96245 shares
CY2015Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2006Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
400000 shares
CY2014Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
16270159 shares
CY2015Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
18145822 shares
CY2014Q4 us-gaap Treasury Stock Value
TreasuryStockValue
458700000 USD
CY2015Q4 us-gaap Treasury Stock Value
TreasuryStockValue
527400000 USD
CY2013 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
-3400000 USD
CY2014 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
-2300000 USD
CY2015 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
-1000000 USD
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
78000000 USD
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1100000 USD
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
900000 USD
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2900000 USD
CY2013 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
1900000 USD
CY2014 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
900000 USD
CY2013 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
121700000 USD
CY2012Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2013Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
300000 USD
CY2014Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2015Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
300000 USD
CY2013 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
46700000 USD
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
700000 USD
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
1700000 USD
CY2012Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
76000000 USD
CY2013Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
400000 USD
CY2014Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
900000 USD
CY2015Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
2900000 USD
CY2015Q4 us-gaap Unrecorded Unconditional Purchase Obligation Due After Five Years
UnrecordedUnconditionalPurchaseObligationDueAfterFiveYears
7200000 USD
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-9100000 USD
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-7700000 USD
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4600000 USD
CY2013 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
21600000 USD
CY2014 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
21700000 USD
CY2015 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
18600000 USD
CY2015Q4 us-gaap Unrecorded Unconditional Purchase Obligation Balance On Third Anniversary
UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary
21100000 USD
CY2015Q4 us-gaap Unrecorded Unconditional Purchase Obligation Balance On Fifth Anniversary
UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary
11900000 USD
CY2015Q4 us-gaap Unrecorded Unconditional Purchase Obligation Balance On First Anniversary
UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary
33300000 USD
CY2015Q4 us-gaap Unrecorded Unconditional Purchase Obligation Balance On Fourth Anniversary
UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary
12600000 USD
CY2015Q4 us-gaap Unrecorded Unconditional Purchase Obligation Balance On Second Anniversary
UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary
28200000 USD
CY2013 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
102100000 shares
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
100700000 shares
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101000000 shares
CY2013 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88100000 shares
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86800000 shares
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
89400000 shares
CY2015 us-gaap Revenue Recognition Accounting Policy Gross And Net Revenue Disclosure
RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Operating Revenues&#8212;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We derived consolidated </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net operating revenues</font><font style="font-family:inherit;font-size:10pt;"> from the following payor sources:</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td width="62%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Managed care and other discount plans, including Medicare Advantage</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other third-party payors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Workers' compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patients</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We record gross service charges in our accounting records on an accrual basis using our established rates for the type of service provided to the patient. We recognize an estimated contractual allowance and an estimate of potential subsequent adjustments that may arise from post-payment and other reviews to reduce gross patient charges to the amount we estimate we will actually realize for the service rendered based upon previously agreed to rates with a payor. Our accounting systems calculate contractual allowances on a patient-by-patient basis based on the rates in effect for each primary third-party payor.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms that result from contract renegotiations and renewals. Due to complexities involved in determining amounts ultimately due under reimbursement arrangements with third-party payors, which are often subject to interpretation, we may receive reimbursement for healthcare services authorized and provided that is different from our estimates, and such differences could be material. In addition, laws and regulations governing the Medicare and Medicaid programs are complex, subject to interpretation, and are routinely modified for provider reimbursement. All healthcare providers participating in the Medicare and Medicaid programs are required to meet certain financial reporting requirements. Federal regulations require submission of annual cost reports covering medical costs and expenses associated with the services provided under each hospital, home health, and hospice provider number to program beneficiaries. Annual cost reports required under the Medicare and Medicaid programs are subject to routine audits, which may result in adjustments to the amounts ultimately determined to be due to HealthSouth under these reimbursement programs. These audits often require several years to reach the final determination of amounts earned under the programs. If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CMS has been granted authority to suspend payments, in whole or in part, to Medicare providers if CMS possesses reliable information an overpayment, fraud, or willful misrepresentation exists. If CMS suspects payments are being made as the result of fraud or misrepresentation, CMS may suspend payment at any time without providing prior notice to us. The initial suspension period is limited to </font><font style="font-family:inherit;font-size:10pt;">180</font><font style="font-family:inherit;font-size:10pt;"> days. However, the payment suspension period can be extended almost indefinitely if the matter is under investigation by the United States Department of Health and Human Services Office of Inspector General (the &#8220;HHS-OIG&#8221;) or the United States Department of Justice. Therefore, we are unable to predict if or when we may be subject to a suspension of payments by the Medicare and/or Medicaid programs, the possible length of the suspension period, or the potential cash flow impact of a payment suspension. Any such suspension would adversely impact our financial position, results of operations, and cash flows.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to legislative directives and authorizations from Congress, CMS has developed and instituted various Medicare audit programs under which CMS contracts with private companies to conduct claims and medical record audits. As a matter of course, we undertake significant efforts through training and education to ensure compliance with Medicare requirements. However, audits may lead to assertions we have been underpaid or overpaid by Medicare or submitted improper claims in some instances, require us to incur additional costs to respond to requests for records and defend the validity of payments and claims, and ultimately require us to refund any amounts determined to have been overpaid. We cannot predict when or how these audit programs will affect us.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Inpatient Rehabilitation Revenues</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our inpatient rehabilitation segment derived its </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net operating revenues</font><font style="font-family:inherit;font-size:10pt;"> from the following payor sources:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td width="62%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Managed care and other discount plans, including Medicare Advantage</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other third-party payors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Workers&#8217; compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patients</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues recognized by our inpatient rehabilitation segment are subject to a number of elements which impact both the overall amount of revenue realized as well as the timing of the collection of the related accounts receivable. Factors that are considered and could influence the level of our reserves include the patient&#8217;s total length of stay for in-house patients, each patient&#8217;s discharge destination, the proportion of patients with secondary insurance coverage and the level of reimbursement under that secondary coverage, and the amount of charges that will be disallowed by payors. Such additional factors are assumed to remain consistent with the experience for patients discharged in similar time periods for the same payor classes, and additional reserves are provided to account for these factors.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with CMS approved and announced Recovery Audit Contractors (&#8220;RACs&#8221;) audits related to inpatient rehabilitation facilities (&#8220;IRFs&#8221;), we received requests in 2014 and 2013 to review certain patient files for discharges occurring from 2010 to 2014. These post-payment RAC audits are focused on medical necessity requirements for admission to IRFs rather than targeting a specific diagnosis code as in previous pre-payment audits. Medical necessity is an assessment by an independent physician of a patient&#8217;s ability to tolerate and benefit from intensive multi-disciplinary therapy provided in an IRF setting.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, the Medicare payments that are subject to these audit requests represent less than </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;"> of our Medicare patient discharges from 2010 to 2014, and not all of these patient file requests have resulted in payment denial determinations by the RACs. Because we have confidence in the medical judgment of both the referring and the admitting physicians who assess the treatment needs of their patients, we have appealed substantially all RAC denials arising from these audits using the same process we follow for appealing denials of certain diagnosis codes by Medicare Administrative Contractors (&#8220;MACs&#8221;) (see &#8220;Accounts Receivable and Allowance for Doubtful Accounts&#8221; below). Due to the delays announced by CMS in the related adjudication process, we believe the resolution of any claims that are subsequently denied as a result of these RAC audits could take in excess of three years. In addition, because we have limited experience with RACs in the context of post-payment reviews of this nature, we cannot provide assurance as to the future success of these disputes. As such, we make provisions for these claims based on our historical experience and success rates in the claims adjudication process, which is the same process we follow for appealing denials of certain diagnosis codes by MACs. As the ultimate results of these audits impact our estimates of amounts determined to be due to HealthSouth under these reimbursement programs, our provision for claims that are part of this post-payment review process are recorded to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net operating revenues</font><font style="font-family:inherit;font-size:10pt;">. During 2015 and 2014, we adjusted our </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net operating revenues</font><font style="font-family:inherit;font-size:10pt;"> by approximately </font><font style="font-family:inherit;font-size:10pt;">($0.6) million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, for post-payment claims that are part of this review process.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Home Health and Hospice Revenues</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for our home health and hospice segment in 2014 and 2013 included only the results of HealthSouth&#8217;s legacy hospital-based home health agencies. Our home health and hospice segment derived its </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net operating revenues</font><font style="font-family:inherit;font-size:10pt;"> from the following payor sources:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td width="62%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Managed care and other discount plans, including Medicare Advantage</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other third-party payors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Workers&#8217; compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patients</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Home health and hospice revenues are earned as services are performed either on an episode of care basis, on a per visit basis, or on a daily basis, depending upon the payment terms and conditions established with each payor for services provided.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Home Health</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Medicare home health prospective payment system, we are paid by Medicare based on episodes of care. An episode of care is defined as a length of stay up to 60 days, with multiple continuous episodes allowed. A base episode payment is established by the Medicare program through federal legislation. The base episode payment can be adjusted based on each patient&#8217;s health including clinical condition, functional abilities, and service needs, as well as for the applicable geographic wage index, low utilization, patient transfers, and other factors. The services covered by the episode payment include all disciplines of care in addition to medical supplies.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A portion of reimbursement from each Medicare episode is billed near the start of each episode, and cash is typically received before all services are rendered. Revenue for the episode of care is recorded over an average length of treatment period using a calendar day prorating method. The amount of revenue recognized for episodes of care which are incomplete at period end is based on the pro rata number of days in the episode which have been completed as of the period end date. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the difference between the cash received from Medicare for a request for anticipated payment on episodes in progress and the associated estimated revenue was not material and was recorded in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</font><font style="font-family:inherit;font-size:10pt;"> in our condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to certain Medicare regulations affecting outlier revenue if our patient&#8217;s care was unusually costly. Regulations require a cap on all outlier revenue at 10% of total Medicare revenue received by each provider during a cost reporting year. Management has reviewed the potential cap. Reserves recorded for the outlier cap were not material as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For episodic-based rates that are paid by other insurance carriers, including Medicare Advantage, we recognize revenue in a similar manner as discussed above for Medicare revenues. However, these rates can vary based upon the negotiated terms. For non-episodic-based revenue, gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual allowances are recorded for the differences between our standard rates and the applicable contracted rates.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hospice</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare revenues for hospice are recorded on an accrual basis based on the number of days a patient has been on service at amounts equal to an estimated daily or hourly payment rate. The payment rate is dependent on whether a patient is receiving routine home care, general inpatient care, continuous home care or respite care. Adjustments to Medicare revenues are recorded based on an inability to obtain appropriate billing documentation or authorizations acceptable to the payor or other reasons unrelated to credit risk. Hospice companies are subject to two specific payment limit caps under the Medicare program. One limit relates to inpatient care days that exceed 20% of the total days of hospice care provided for the year. The second limit relates to an aggregate Medicare reimbursement cap calculated by the Medicare fiscal intermediary. Currently, we do not believe we are at risk for exceeding these caps and have not recorded a reserve for these caps as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For non-Medicare hospice revenues, we record gross revenue on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual adjustments are recorded for the difference between our established rates and the amounts estimated to be realizable from patients and third parties for services provided and are deducted from gross revenue to determine our net service revenue.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to changes in government legislation that could impact Medicare payment levels and changes in payor patterns that may impact the level and timing of payments for services rendered.</font></div></div>
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates and Assumptions&#8212;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of our consolidated financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions are used for, but not limited to: (1)&#160;allowance for contractual revenue adjustments; (2)&#160;allowance for doubtful accounts; (3) fair value of acquired assets and assumed liabilities in business combinations; (4)&#160;asset impairments, including goodwill; (5)&#160;depreciable lives of assets; (6)&#160;useful lives of intangible assets; (7)&#160;economic lives and fair value of leased assets; (8)&#160;income tax valuation allowances; (9)&#160;uncertain tax positions; (10)&#160;fair value of stock options and restricted stock containing a market condition; (11)&#160;fair value of redeemable noncontrolling interests; (12)&#160;reserves for self-insured healthcare plans; (13) reserves for professional, workers&#8217; compensation, and comprehensive general insurance liability risks; and (14)&#160;contingency and litigation reserves. Future events and their effects cannot be predicted with certainty; accordingly, our accounting estimates require the exercise of judgment. The accounting estimates used in the preparation of our consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained, and as our operating environment changes. We evaluate and update our assumptions and estimates on an ongoing basis and may employ outside experts to assist in our evaluation, as considered necessary. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name View Source Status
0000785161-16-000117-index-headers.html Edgar Link pending
0000785161-16-000117-index.html Edgar Link pending
0000785161-16-000117.txt Edgar Link pending
0000785161-16-000117-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hls-20151231.xml Edgar Link completed
hls-20151231.xsd Edgar Link pending
hls-20151231_cal.xml Edgar Link unprocessable
hls-20151231_def.xml Edgar Link unprocessable
hls-20151231_lab.xml Edgar Link unprocessable
hls-20151231_pre.xml Edgar Link unprocessable
hls10-k123115ex1019.htm Edgar Link pending
hls10-k123115ex1020.htm Edgar Link pending
hls10-k123115ex21.htm Edgar Link pending
hls10-k123115ex22.htm Edgar Link pending
hls10k123115.htm Edgar Link pending
hls10k123115ex121.htm Edgar Link pending
hls10k123115ex211.htm Edgar Link pending
hls10k123115ex231.htm Edgar Link pending
hls10k123115ex311.htm Edgar Link pending
hls10k123115ex312.htm Edgar Link pending
hls10k123115ex321.htm Edgar Link pending
hls10k123115ex322.htm Edgar Link pending
hls10k1231_chart-06434a02.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R100.htm Edgar Link pending
R101.htm Edgar Link pending
R102.htm Edgar Link pending
R103.htm Edgar Link pending
R104.htm Edgar Link pending
R105.htm Edgar Link pending
R106.htm Edgar Link pending
R107.htm Edgar Link pending
R108.htm Edgar Link pending
R109.htm Edgar Link pending
R11.htm Edgar Link pending
R110.htm Edgar Link pending
R111.htm Edgar Link pending
R112.htm Edgar Link pending
R113.htm Edgar Link pending
R114.htm Edgar Link pending
R115.htm Edgar Link pending
R116.htm Edgar Link pending
R117.htm Edgar Link pending
R118.htm Edgar Link pending
R119.htm Edgar Link pending
R12.htm Edgar Link pending
R120.htm Edgar Link pending
R121.htm Edgar Link pending
R122.htm Edgar Link pending
R123.htm Edgar Link pending
R124.htm Edgar Link pending
R125.htm Edgar Link pending
R126.htm Edgar Link pending
R127.htm Edgar Link pending
R128.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
R92.htm Edgar Link pending
R93.htm Edgar Link pending
R94.htm Edgar Link pending
R95.htm Edgar Link pending
R96.htm Edgar Link pending
R97.htm Edgar Link pending
R98.htm Edgar Link pending
R99.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending